Diagnostic Evaluation of an Increased Risk of Developing Small Intestinal Bacterial Overgrowth Associated with Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Dual GLP-1/GIP Receptor Agonists: A Global Retrospective Multicenter Cohort Analysis.
Level 3 - non-randomized controlled study
Retrospective propensity score-matched cohort study using electronic health records.
PubMed 40941750 · doi:10.3390/diagnostics15172264
What was done
Using the TriNetX global electronic health records database (2006–2024), researchers conducted a retrospective cohort study of adult type 2 diabetes mellitus patients initiating GLP-1 receptor agonists or dual GLP-1/GIP receptor agonists versus other second-line diabetes agents. Patients with conditions predisposing to small intestinal bacterial overgrowth (SIBO)—such as major abdominal surgery, connective tissue disorders, or gastroparesis—were excluded. Following 1:1 propensity score matching (216,173 patients per cohort), short-term (<1 year) and long-term (up to 5 years) risks of incident SIBO were assessed using Kaplan-Meier analysis and univariable Cox proportional hazards models.
What was found
In the short-term analysis (<1 year), patients receiving GLP-1 or dual GLP-1/GIP receptor agonists had a higher incidence of diagnostically confirmed SIBO compared to those on other second-line agents (0.177 vs. 0.083 per 1,000 patient-years; HR 2.14, 95% CI 1.13–4.07, p = 0.0491). Long-term analysis up to 5 years showed a non-significant hazard ratio trend in Cox modeling (HR 2.02, 95% CI 0.98–4.12), though Kaplan-Meier analysis demonstrated sustained curve divergence (p = 0.017).
Why it matters
Because GLP-1 receptor agonists delay gastrointestinal transit, these findings provide real-world clinical evidence supporting a biologically plausible risk of SIBO. They suggest clinicians should maintain suspicion and consider breath testing for patients who develop persistent abdominal symptoms following GLP-1 initiation.
Limits
The study is limited by retrospective electronic health record and coding-based data, which risk underreporting or misclassification of SIBO. Absolute event rates were very low in both arms (<0.2 cases per 1,000 patient-years), leading to wide confidence intervals that bordered statistical insignificance, and unmeasured confounders like specific dietary patterns or exact glycemic control could not be fully controlled.
Cited by
- contradicts GLP-1 receptor agonists slow motility through the gut, which helps with conditions such as SIBO, Candida, and H. pylori.